USA Pharma News | Healthcare News 2/5

top of page

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

ipharmaservices

Mar 28, 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

ipharmaservices

Mar 4, 2024

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

ipharmaservices

Feb 14, 2024

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

ipharmaservices

Jan 10, 2023

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

ipharmaservices

Oct 9, 2022

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

ipharmaservices

Sep 1, 2022

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

ipharmaservices

Jun 16, 2022

Myasthenia Gravis News | FDA and EMA approvals |

Myasthenia Gravis News | FDA and EMA approvals |

Myasthenia Gravis News | FDA and EMA approvals |

ipharmaservices

Dec 22, 2021

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

ipharmaservices

Nov 10, 2021

FDA approved Novartis Scembli for chronic myeloid leukemia

FDA approved Novartis Scembli for chronic myeloid leukemia

FDA approved Novartis Scembli for chronic myeloid leukemia

ipharmaservices

Nov 2, 2021

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

ipharmaservices

Jun 8, 2021

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

ipharmaservices

Apr 23, 2021

BMS’ and bluebird bio’s Abecma approved by US FDA; first CAR T cell therapy for multiple myeloma

ipharmaservices

Mar 28, 2021

Novartis’ blockbuster Entresto received the US FDA approval for a broader target population

ipharmaservices

Feb 21, 2021

US FDA approved BMS gene therapy Breyanzi

US FDA approved BMS gene therapy Breyanzi

US FDA approved BMS gene therapy Breyanzi

ipharmaservices

Feb 8, 2021

Merck and Bayer announced the US FDA approval for Verquvo

ipharmaservices

Jan 21, 2021

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

ipharmaservices

Jan 12, 2021

Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients

ipharmaservices

Jan 12, 2021

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

ipharmaservices

Oct 18, 2020

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

ipharmaservices

Sep 26, 2020

bottom of page